<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="letter">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Emerg Infect Dis</journal-id>
      <journal-id journal-id-type="iso-abbrev">Emerging Infect. Dis</journal-id>
      <journal-id journal-id-type="publisher-id">EID</journal-id>
      <journal-title-group>
        <journal-title>Emerging Infectious Diseases</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1080-6040</issn>
      <issn pub-type="epub">1080-6059</issn>
      <publisher>
        <publisher-name>Centers for Disease Control and Prevention</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">26196738</article-id>
      <article-id pub-id-type="pmc">4517722</article-id>
      <article-id pub-id-type="publisher-id">15-0524</article-id>
      <article-id pub-id-type="doi">10.3201/eid2108.150524</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Letters to the Editor</subject>
        </subj-group>
        <subj-group subj-group-type="article-type">
          <subject>Letter</subject>
        </subj-group>
        <subj-group subj-group-type="TOC-title">
          <subject>Malaria Prophylaxis Failure with Doxycycline, Central African Republic, 2014</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Malaria Prophylaxis Failure with Doxycycline, Central African Republic, 2014</article-title>
        <alt-title alt-title-type="running-head">Malaria Prophylaxis Failure with Doxycycline</alt-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Madamet</surname>
            <given-names>Marylin</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Gaillard</surname>
            <given-names>Tiphaine</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Velut</surname>
            <given-names>Guillaume</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ficko</surname>
            <given-names>Cecile</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Houz&#xE9;</surname>
            <given-names>Pascal</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Bylicki</surname>
            <given-names>Claire</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>M&#xE9;rat</surname>
            <given-names>St&#xE9;phane</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Houz&#xE9;</surname>
            <given-names>Sandrine</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Taudon</surname>
            <given-names>Nicolas</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Michel</surname>
            <given-names>R&#xE9;my</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Pasquier</surname>
            <given-names>Pierre</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Rapp</surname>
            <given-names>Christophe</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Pradines</surname>
            <given-names>Bruno</given-names>
          </name>
        </contrib>
        <aff id="aff1">Institut de Recherche Biom&#xE9;dicale des Arm&#xE9;es, Br&#xE9;tigny sur Orge, France (M. Madamet, N. Taudon, B. Pradines); </aff>
        <aff id="aff2">Aix Marseille Universit&#xE9;, Marseille, France (M. Madamet, N. Taudon, B. Pradines); </aff>
        <aff id="aff3">Centre National de R&#xE9;f&#xE9;rence du Paludisme, Marseille (M. Madamet, N. Taudon, B. Pradines); </aff>
        <aff id="aff4">H&#xF4;pital d&#x2019;Instruction des Arm&#xE9;es Saint Anne, Toulon, France (T. Gaillard); </aff>
        <aff id="aff5">Centre d&#x2019;Epid&#xE9;miologie et de Sant&#xE9; Publique des Arm&#xE9;es, </aff>
        <aff id="aff6">Marseille, France (G. Velut, R. Michel); </aff>
        <aff id="aff7">H&#xF4;pital d&#x2019;Instruction des Arm&#xE9;es Begin, Saint Mand&#xE9;, France (C. Ficko, S. M&#xE9;rat, P. Pasquier, C. Rapp); </aff>
        <aff id="aff8">H&#xF4;pital Saint-Louis, Paris, France (P. Houz&#xE9;); </aff>
        <aff id="aff9">H&#xF4;pital Bichat Claude Bernard, Paris (S. Houz&#xE9;); </aff>
        <aff id="aff10">Institut pour la Recherche et le D&#xE9;veloppement, Paris (S. Houz&#xE9;), </aff>
        <aff id="aff11">Universit&#xE9; Paris Descartes, Paris (S. Houz&#xE9;); </aff>
        <aff id="aff12">Centre National de R&#xE9;f&#xE9;rence du Paludisme, Paris (S. Houz&#xE9;); </aff>
        <aff id="aff13">Antenne M&#xE9;dicale de Fontevraud, Fontevraud, France (C. Bylicki); </aff>
        <aff id="aff14">Ecole du Val-de-Gr&#xE2;ce, Paris (R. Michel, C. Rapp)</aff>
      </contrib-group>
      <author-notes>
        <corresp id="cor1">Address for correspondence: Bruno Pradines, Unit&#xE9; de parasitologie et d&#x2019;entomologie, Institut de recherche biom&#xE9;dicale des Arm&#xE9;es, BP 73, 91223 Br&#xE9;tigny sur Orge, France; email: <email xlink:href="bruno.pradines@free.fr">bruno.pradines@free.fr</email></corresp>
      </author-notes>
      <pub-date pub-type="ppub">
        <month>8</month>
        <year>2015</year>
      </pub-date>
      <volume>21</volume>
      <issue>8</issue>
      <fpage>1485</fpage>
      <lpage>1486</lpage>
      <kwd-group kwd-group-type="author">
        <title>Keywords: </title>
        <kwd>malaria</kwd>
        <kwd>parasites</kwd>
        <kwd>Plasmodium falciparum</kwd>
        <kwd>doxycycline</kwd>
        <kwd>Central African Republic</kwd>
        <kwd>antimalarial drug</kwd>
        <kwd>France</kwd>
        <kwd>antimicrobial resistance</kwd>
        <kwd>prophylaxis</kwd>
        <kwd>travel</kwd>
        <kwd>in vitro</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <p><bold>To the Editor:</bold> Doxycycline is an effective antimalarial prophylactic drug when administered as a monotherapy 1 day before, daily during, and for 4 weeks after travel to an area where malaria is endemic (<xref rid="R1" ref-type="bibr"><italic>1</italic></xref>). Doxycycline is currently a recommended chemoprophylactic regimen for travelers visiting areas where malaria is endemic and has a high prevalence of chloroquine or multidrug resistance (<xref rid="R2" ref-type="bibr"><italic>2</italic></xref>). The World Health Organization also recommends doxycycline in combination with quinine or artesunate as the second-line treatment for uncomplicated <italic>Plasmodium falciparum</italic> malaria (<xref rid="R3" ref-type="bibr"><italic>3</italic></xref>).</p>
    <p>Prophylactic and clinical failures of doxycycline against <italic>P. falciparum</italic> have been associated with both inadequate doses (<xref rid="R4" ref-type="bibr"><italic>4</italic></xref>) and poor patient compliance (<xref rid="R5" ref-type="bibr"><italic>5</italic></xref>). However, resistance can also explain failures of prophylaxis. Cycline resistance in <italic>Plasmodium</italic> spp. has been documented as a consequence of selective drug pressure in a <italic>P. berghei</italic> murine malaria model (<xref rid="R6" ref-type="bibr"><italic>6</italic></xref>). The administration of increasing doses of minocycline to mice infected with 1 &#xD7; 10<sup>7</sup> parasites for 86 successive passages over 600 days made it possible to obtain a resistant <italic>P. berghei</italic> strain with a median drug inhibitory concentration (IC<sub>50</sub>) of 600 mg/kg/d, which is 6-fold higher than that of the susceptible starting strain (100 mg/kg/d) (<xref rid="R6" ref-type="bibr"><italic>6</italic></xref>). A Bayesian mixture modeling approach identified 3 different phenotypes (low, medium, and high doxycycline IC<sub>50</sub> phenotypic groups) among <italic>P. falciparum</italic> clinical isolates (<xref rid="R7" ref-type="bibr"><italic>7</italic></xref><italic>,</italic><xref rid="R8" ref-type="bibr"><italic>8</italic></xref>). Using 90 isolates from 14 countries, we demonstrated that increases in copy numbers of <italic>P. falciparum</italic> metabolite drug transporter gene (<italic>Pfmdt</italic>, PFE0825w) and <italic>P. falciparum</italic> GTPase TetQ gene (<italic>PfTetQ</italic>, PFL1710c) are associated with reduced susceptibility to doxycycline (<xref rid="R9" ref-type="bibr"><italic>9</italic></xref>); this association was later confirmed (<xref rid="R7" ref-type="bibr"><italic>7</italic></xref>). In addition, isolates with <italic>PfTetQ</italic> KYNNNN motif repeats are associated with in vitro reduced susceptibility to doxycycline and with a significantly higher probability of having an IC<sub>50</sub> above the doxycycline resistance threshold of 35 &#x3BC;M (<xref rid="R9" ref-type="bibr"><italic>9</italic></xref><italic>,</italic><xref rid="R10" ref-type="bibr"><italic>10</italic></xref>).</p>
    <p>We report a case of documented malaria prophylactic failure with doxycycline in a 26-year-old soldier from France who was infected during a 6-week peacekeeping mission in the Central African Republic in 2014. According to his colleagues and the collective prophylaxis intake, the patient had been compliant with doxycycline prophylaxis. On admission to a hospital in Bangui, Central African Republic, the patient had fever (temperature 40&#xB0;C), alteration of consciousness, and hypotension. The diagnosis of severe <italic>P. falciparum</italic> malaria was made on the basis of a rapid diagnostic test confirmed by a blood smear test (parasitemia 8% on day 0). Intravenous artesunate was immediately started, in accordance with World Health Organization recommendations (<xref rid="R3" ref-type="bibr"><italic>3</italic></xref>). The patient&#x2019;s clinical condition worsened, and kidney failure developed. Twenty-four hours later (day 1), he was transported by airplane to B&#xE9;gin Military Teaching Hospital (Saint-Mand&#xE9;, France). On admission, he had cerebral edema and a <italic>P. falciparum</italic> parasitemia level of 0.7%. The patient died 1 day later (day 2).</p>
    <p>A blood sample obtained from the patient on day 1 in France showed a doxycycline concentration of 195 &#x3BC;g/mL plasma. This concentration, which was determined by liquid chromatography coupled with tandem mass spectrometry, was compatible with a last doxycycline uptake 1 day before diagnosis (day &#x2212;1). The finding of the expected doxycycline plasma concentration, together with assurances (colleague&#x2019;s statements and collective intake of doxycycline) that the patient had followed the drug regimen, was sufficient to suggest prophylaxis failure in a treatment-compliant patient. </p>
    <p>The <italic>P. falciparum</italic> sample obtained from the patient on arrival in France was evaluated for in vitro susceptibility to doxycycline, but the evaluation was unsuccessful. The number of copies of <italic>PfTetQ</italic> and <italic>Pfmdt</italic> genes were evaluated relative to the single-copy <italic>P. falciparum &#x3B2;-tubulin</italic> gene (<italic>pf&#x3B2;tubulin</italic>), as previously described (<xref rid="R7" ref-type="bibr"><italic>7</italic></xref><italic>,</italic><xref rid="R8" ref-type="bibr"><italic>8</italic></xref>). The sample was assayed in triplicate. The 2<sup>&#x2013;&#x394;&#x394;Ct</sup> method (where C<italic><sub>t</sub></italic> indicates cycle threshold) of relative quantification was used and adapted to estimate the number of copies of <italic>Pfmdt</italic> and <italic>PfTetQ</italic> by using the formula &#x394;&#x394;C<sub>t</sub> = (C<sub>t (</sub><italic><sub>PfTetQ</sub></italic>
<sub>or</sub>
<italic><sub>Pfmdt</sub></italic><sub>)</sub> &#x2212; C<sub>t (</sub><italic><sub>Pf&#x3B2;tubulin</sub></italic><sub>)</sub>)<sub>Sample</sub> &#x2013; (C<sub>t (</sub><italic><sub>PfTetQ</sub></italic>
<sub>or</sub>
<italic><sub>Pfmdt</sub></italic><sub>)</sub> &#x2212; C<sub>t (</sub><italic><sub>Pf&#x3B2;tubulin</sub></italic><sub>)</sub>)<sub>Calibrator</sub>. Genomic DNA extracted from 3D7 <italic>P. falciparum</italic>, which has a single copy of each gene, was used for calibrator sample; <italic>Pf&#x3B2;tubulin</italic> served as the control housekeeping gene. The experiment was assayed twice. The sample had 2 copies of <italic>PfTetQ</italic> and <italic>Pfmdt</italic> genes, which suggested decreased in vitro susceptibility of the sample to doxycycline (<xref rid="R8" ref-type="bibr"><italic>8</italic></xref><italic>,</italic><xref rid="R9" ref-type="bibr"><italic>9</italic></xref>). The genotyping of <italic>PfTetQ</italic> sequence polymorphisms was done by using conventional methods with the primers <italic>PfTetQ</italic> forward (5&#x2032;-TCACGACAAATGTGCTAGATAC-3&#x2032;) and <italic>PfTetQ</italic> reverse (5&#x2032;-ATCATCATTTGTGGTGGATAT-3&#x2032;), as previously described (<xref rid="R10" ref-type="bibr"><italic>10</italic></xref>). Two <italic>PfTetQ</italic> KYNNNN motif repeats were found in the sample; &lt;3 KYNNNN motif repeats are predictive of in vitro <italic>P. falciparum</italic>&#x2013;resistant parasites with an IC<sub>50</sub> of &gt;35 &#x3BC;M (odds ratio 15) (<xref rid="R10" ref-type="bibr"><italic>10</italic></xref>). The 2 copies of <italic>Pfmdt</italic> and the 2 KYNNNN motif repeats have been shown to be associated with parasites with in vitro resistance to doxycycline (<xref rid="R9" ref-type="bibr"><italic>9</italic></xref><italic>,</italic><xref rid="R10" ref-type="bibr"><italic>10</italic></xref>). The association of doxycycline resistance (prophylactic failure with statement of correct intake and the presence of an expected concentration) with increased <italic>Pfmdt</italic> copies and decreased <italic>PfTetQ</italic> KYNNNN motif repeats suggest that these molecular markers are predictive markers of doxycycline resistance that can be used for resistance surveillance.</p>
  </body>
  <back>
    <fn-group>
      <fn fn-type="citation">
        <p><italic>Suggested citation for this article</italic>: Madamet M, Gaillard T, Velut G, Ficko C, Houz&#xE9; P, Bylicki C, et al. Malaria prophylaxis failure with doxycycline, Central African Republic, 2014 [letter]. Emerg Infect Dis. 2015 Aug [<italic>date cited</italic>]. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.3201/eid2108.150524">http://dx.doi.org/10.3201/eid2108.150524</ext-link></p>
      </fn>
    </fn-group>
    <ref-list>
      <title>References</title>
      <ref id="R1">
        <label>1. </label>
        <mixed-citation publication-type="journal"><string-name><surname>Briolant</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Fusa&#xEF;</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Rogier</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Pradines</surname>
<given-names>B</given-names></string-name>. <article-title>Tetracycline antibiotics in malaria.</article-title>
<source>Open Trop Med J.</source>
<year>2008</year>;<volume>1</volume>:<fpage>31</fpage>&#x2013;<lpage>46</lpage>. <pub-id pub-id-type="doi">10.2174/1874315300801010031</pub-id></mixed-citation>
      </ref>
      <ref id="R2">
        <label>2. </label>
        <mixed-citation publication-type="journal"><collab>Institut National de Veille Sanitaire</collab>. <article-title>Recommandations sanitaires pour les voyageurs, 2014.</article-title>
<comment>Bulletin Epid&#xE9;miologique Hebdomadaire</comment>
<year>2014</year>;<volume>16&#x2013;17</volume>:<fpage>264</fpage>&#x2013;<lpage>311</lpage>.</mixed-citation>
      </ref>
      <ref id="R3">
        <label>3. </label>
        <mixed-citation publication-type="book"><collab>World Health Organization</collab>. Guidelines for the treatment of malaria, 2nd ed. Geneva: The Organization; <year>2010</year>.</mixed-citation>
      </ref>
      <ref id="R4">
        <label>4. </label>
        <mixed-citation publication-type="journal"><string-name><surname>Pang</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Limsomwong</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Singharaj</surname>
<given-names>P</given-names></string-name>. <article-title>Prophylactic treatment of vivax and falciparum malaria with low-dose doxycycline.</article-title>
<source>J Infect Dis</source>. <year>1988</year>;<volume>158</volume>:<fpage>1124</fpage>&#x2013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1093/infdis/158.5.1124</pub-id><pub-id pub-id-type="pmid">3053925</pub-id></mixed-citation>
      </ref>
      <ref id="R5">
        <label>5. </label>
        <mixed-citation publication-type="journal"><string-name><surname>Wallace</surname>
<given-names>MR</given-names></string-name>, <string-name><surname>Sharp</surname>
<given-names>TW</given-names></string-name>, <string-name><surname>Smoak</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Iriye</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Rozmajzl</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Thornton</surname>
<given-names>SA</given-names></string-name>, <etal/>
<article-title>Malaria among United States troops in Somalia.</article-title>
<source>Am J Med</source>. <year>1996</year>;<volume>100</volume>:<fpage>49</fpage>&#x2013;<lpage>55</lpage>. <pub-id pub-id-type="doi">10.1016/S0002-9343(96)90011-X</pub-id><pub-id pub-id-type="pmid">8579087</pub-id></mixed-citation>
      </ref>
      <ref id="R6">
        <label>6. </label>
        <mixed-citation publication-type="journal"><string-name><surname>Jacobs</surname>
<given-names>RL</given-names></string-name>, <string-name><surname>Koontz</surname>
<given-names>LC</given-names></string-name>. <article-title><italic>Plasmodium berghei</italic>: development of resistance to clindamycin and minocycline in mice.</article-title>
<source>Exp Parasitol</source>. <year>1976</year>;<volume>40</volume>:<fpage>116</fpage>&#x2013;<lpage>23</lpage>. <pub-id pub-id-type="doi">10.1016/0014-4894(76)90073-4</pub-id><pub-id pub-id-type="pmid">780118</pub-id></mixed-citation>
      </ref>
      <ref id="R7">
        <label>7. </label>
        <mixed-citation publication-type="journal"><string-name><surname>Briolant</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Baragatti</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Parola</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Simon</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Tall</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Sokhna</surname>
<given-names>C</given-names></string-name>, <etal/>
<article-title>Multinormal in vitro distribution model suitable for the distribution of <italic>Plasmodium falciparum</italic> chemosusceptibility to doxycycline.</article-title>
<source>Antimicrob Agents Chemother</source>. <year>2009</year>;<volume>53</volume>:<fpage>688</fpage>&#x2013;<lpage>95</lpage>. <pub-id pub-id-type="doi">10.1128/AAC.00546-08</pub-id><pub-id pub-id-type="pmid">19047651</pub-id></mixed-citation>
      </ref>
      <ref id="R8">
        <label>8. </label>
        <mixed-citation publication-type="journal"><string-name><surname>Gaillard</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Briolant</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Houz&#xE9;</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Baragatti</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Wurtz</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Hubert</surname>
<given-names>V</given-names></string-name>, <etal/>
<article-title><italic>PftetQ</italic> and <italic>pfmdt</italic> copy numbers as predictive molecular markers of decreased ex vivo doxycycline susceptibility in imported <italic>Plasmodium falciparum</italic> malaria.</article-title>
<source>Malar J</source>. <year>2013</year>;<volume>12</volume>:<fpage>414</fpage>. <pub-id pub-id-type="doi">10.1186/1475-2875-12-414</pub-id><pub-id pub-id-type="pmid">24225377</pub-id></mixed-citation>
      </ref>
      <ref id="R9">
        <label>9. </label>
        <mixed-citation publication-type="journal"><string-name><surname>Briolant</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Wurtz</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Zettor</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Rogier</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Pradines</surname>
<given-names>B</given-names></string-name>. <article-title>Susceptibility of <italic>Plasmodium falciparum</italic> isolates to doxycycline is associated with <italic>pftetQ</italic> sequence polymorphisms and <italic>pftetQ</italic> and <italic>pfmdt</italic> copy numbers.</article-title>
<source>J Infect Dis</source>. <year>2010</year>;<volume>201</volume>:<fpage>153</fpage>&#x2013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1086/648594</pub-id><pub-id pub-id-type="pmid">19929377</pub-id></mixed-citation>
      </ref>
      <ref id="R10">
        <label>10. </label>
        <mixed-citation publication-type="journal"><string-name><surname>Achieng</surname>
<given-names>AO</given-names></string-name>, <string-name><surname>Ingasia</surname>
<given-names>LA</given-names></string-name>, <string-name><surname>Juma</surname>
<given-names>DW</given-names></string-name>, <string-name><surname>Cheruiyot</surname>
<given-names>AC</given-names></string-name>, <string-name><surname>Okudo</surname>
<given-names>CA</given-names></string-name>, <string-name><surname>Yeda</surname>
<given-names>RA</given-names></string-name>, <etal/>
<article-title>Reduced in vitro doxycycline susceptibility in <italic>Plasmodium falciparum</italic> field isolates from Kenya is associated with <italic>PftetQ</italic> KYNNNN sequence polymorphism.</article-title>
<source>Antimicrob Agents Chemother</source>. <year>2014</year>;<volume>58</volume>:<fpage>5894</fpage>&#x2013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1128/AAC.02788-13</pub-id><pub-id pub-id-type="pmid">25070109</pub-id></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
